Results 71 to 80 of about 15,628 (311)

Downregulation of Organic Anion Transporting Polypeptide (OATP) 1B1 Transport Function by Lysosomotropic Drug Chloroquine: Implication in OATP-Mediated Drug-Drug Interactions [PDF]

open access: yes, 2016
Organic anion transporting polypeptide (OATP) 1B1 mediates the hepatic uptake of many drugs including lipid-lowering statins. Decreased OATP1B1 transport activity is often associated with increased systemic exposure of statins and statin-induced myopathy.
Abuznait, Alaa H.   +7 more
core   +2 more sources

Injection‐site and dermatologic reactions associated with glucagon‐like peptide‐1 receptor agonists: Insights from meta‐analysis of randomised controlled trials and real‐world evidence

open access: yesDiabetes, Obesity and Metabolism, EarlyView.
Abstract Aims Glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) are widely used for type 2 diabetes mellitus and obesity, with once‐weekly dosing that supports adherence. However, injection‐site reactions (ISRs) and dermatologic events have been recognised, ranging from mild local events to rare systemic hypersensitivity reactions that may cause ...
Shifa Taj   +6 more
wiley   +1 more source

RxNorm for drug name normalization: a case study of prescription opioids in the FDA adverse events reporting system

open access: yesFrontiers in Bioinformatics
Numerous studies have been conducted on the US Food and Drug Administration (FDA) Adverse Events Reporting System (FAERS) database to assess post-marketing reporting rates for drug safety review and risk assessment. However, the drug names in the adverse
Huyen Le   +9 more
doaj   +1 more source

Incorporating spontaneous reporting system data to aid causal inference in longitudinal healthcare data [PDF]

open access: yes, 2014
Inferring causality using longitudinal observational databases is challenging due to the passive way the data are collected. The majority of associations found within longitudinal observational data are often non-causal and occur due to confounding. The
Aickelin, Uwe, Reps, Jenna M.
core   +4 more sources

Response to Xing et al.: post-marketing safety concerns with Lecanemab: a pharmacovigilance study based on the FDA adverse event reporting system database

open access: yesAlzheimer’s Research & Therapy
A recent paper published a lecanemab analysis with data from the United States Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS) database.
Michael Irizarry   +3 more
doaj   +1 more source

Studying synthesis confinement effects on the internal structure of nanogels in computer simulations [PDF]

open access: yes, 2019
We study the effects of droplet finite size on the structure of nanogel particles synthesized by random crosslinking of molecular polymers diluted in nanoemulsions.
Kantorovich, Sofia S.   +3 more
core   +1 more source

Association between proton pump inhibitors and rhabdomyolysis risk: a post-marketing surveillance using FDA adverse event reporting system (FAERS) database

open access: yesTherapeutic Advances in Drug Safety, 2023
Background: This research aims to explore and compare the signals of rhabdomyolysis from the use of Proton pump inhibitors (PPIs) using the United States Food and Drug Administration Adverse Event Reporting System (FAERS) database.
Ali F. Altebainawi   +4 more
doaj   +1 more source

Drug Safety Monitoring in Children: Performance of Signal Detection Algorithms and Impact of Age Stratification [PDF]

open access: yes, 2016
Introduction: Spontaneous reports of suspected adverse drug reactions (ADRs) can be analyzed to yield additional drug safety evidence for the pediatric population.
Dodd, C.N. (Caitlin)   +5 more
core   +3 more sources

Trend Analysis of Medically Related Osteonecrosis of the Jaw in the United States Using US National Inpatient Data From 2016 to 2022

open access: yesJournal of Public Health Dentistry, EarlyView.
ABSTRACT Objectives This study presents a trend analysis of Medication‐Related Osteonecrosis of the Jaw (MRONJ) using US National Inpatient Sample (NIS) data from 2016 to 2022, providing insights into its epidemiology, comorbidities, and economics.
N. Sheshashayee   +3 more
wiley   +1 more source

A real-world pharmacovigilance study of adverse drug reactions associated with lecanemab and aducanumab based on WHO-VigiAccess and FAERS databases

open access: yesFrontiers in Pharmacology
BackgroundLecanemab and Aducanumab are two novel anti-amyloid beta (Aβ) therapies for Alzheimer’s disease (AD) that have shown promise in slowing cognitive decline. However, their safety profiles remain unclear due to limited real-world evidence.
Haoxiang Hu   +6 more
doaj   +1 more source

Home - About - Disclaimer - Privacy